Efficacy of recombinant human soluble thrombomodulin for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a single arm, non-randomized prospective clinical trial

Table 4 Change in P/F ratio one week after treatment initiation

		Day 1	Day 8
P/F ratio	rhTM group	168 ± 56^,*	215 ± 88^,**
P/F ratio	Untreated group	183 ± 47**	157 ± 55***

Data are expressed as the mean ± standard deviation
P/F ratio PaO₂/FiO₂ ratio
rhTM recombinant human soluble thrombomodulin
*The mean P/F ratio of the rhTM group on day8 was significantly higher than on day1 (two-way ANOVA, p = 0.01)
**The difference between the group mean P/F ratios on day 1 was not significant (two-way ANOVA, p = 0.5)
***The difference between the group mean P/F ratios on day 8 was not significant (two-way ANOVA, p = 0.07)

ISSN: 2049-6958